Use of a non-hepatic cell line highlights limitations associated with cell-based assessment of metabolically induced...

Area of Science:

• Pharmacology
• Drug Discovery
• Toxicology

Background:

• Metabolically induced drug toxicity often leads to late-stage drug development failure.
• In vitro metabolic profiling is crucial for early drug discovery.
• Current methods often use liver cells overexpressing CYP450 enzymes, but endogenous CYP450 activity can interfere.

Purpose of the Study:

• To investigate drug-induced cytotoxicity using a cell line with minimal endogenous metabolic activity.
• To assess the reliability of using single CYP450 isoform overexpression in hepatic cell lines for predicting metabolic toxicity.

Main Methods:

• Utilized kidney-derived HEK293 cells, which lack endogenous CYP450 expression, to minimize background metabolism.
• Overexpressed CYP3A4 in HEK293 cells.
• Exposed cells to four compounds known to cause cytotoxicity in liver cells overexpressing CYP3A4.

Main Results:

• Overexpression of CYP3A4 in HEK293 cells led to increased cell proliferation, not cytotoxicity.
• The four tested compounds did not induce increased cytotoxicity in CYP3A4-expressing HEK293 cells.
• Results suggest that endogenous CYP450 activity in liver cells may confound toxicity assessments.

Conclusions:

• Overexpressing a single CYP450 isoform in hepatic cell lines may not accurately identify the specific enzymes responsible for metabolic toxicity.
• Kidney-derived cell lines offer a potentially more reliable system for studying drug metabolism and toxicity by reducing background interference.